vs
FNB CORP（FNB）与Royalty Pharma plc（RPRX）财务数据对比。点击上方公司名可切换其他公司
Royalty Pharma plc的季度营收约是FNB CORP的1.7倍（$622.0M vs $366.0M），FNB CORP净利率更高（45.9% vs 34.4%，领先11.5%），FNB CORP同比增速更快（13.7% vs 4.8%），过去两年FNB CORP的营收复合增速更高（7.1% vs 4.6%）
FNB集团是总部位于美国宾夕法尼亚州匹兹堡的多元化金融服务机构，为旗下最大子公司第一国民银行的控股主体，截至2025年12月31日总资产超500亿美元，业务覆盖匹兹堡、巴尔的摩、克利夫兰、华盛顿特区、北卡罗来纳州多座城市及南卡罗来纳州查尔斯顿等核心都会区。
本公司是总部位于美国马萨诸塞州剑桥市的临床阶段生物制药企业，专注于研发可调节转化生长因子β（TGF-β）超家族蛋白的药物，该类蛋白在红细胞、肌肉、骨骼、血管等细胞与组织的生长修复过程中发挥核心作用。
FNB vs RPRX — 直观对比
营收规模更大
RPRX
是对方的1.7倍
$366.0M
营收增速更快
FNB
高出8.9%
4.8%
净利率更高
FNB
高出11.5%
34.4%
两年增速更快
FNB
近两年复合增速
4.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $366.0M | $622.0M |
| 净利润 | $168.0M | $214.2M |
| 毛利率 | — | — |
| 营业利润率 | 45.1% | 62.4% |
| 净利率 | 45.9% | 34.4% |
| 营收同比 | 13.7% | 4.8% |
| 净利润同比 | 52.7% | 2.9% |
| 每股收益（稀释后） | $0.47 | $0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FNBRPRX
| Q4 25 | $366.0M | $622.0M | ||
| Q3 25 | $359.0M | $609.3M | ||
| Q2 25 | $348.0M | $578.7M | ||
| Q1 25 | $323.0M | $568.2M | ||
| Q4 24 | $322.0M | $593.6M | ||
| Q3 24 | $323.0M | $564.7M | ||
| Q2 24 | $316.0M | $537.3M | ||
| Q1 24 | $319.0M | $568.0M |
净利润FNBRPRX
| Q4 25 | $168.0M | $214.2M | ||
| Q3 25 | $150.0M | $288.2M | ||
| Q2 25 | $130.0M | $30.2M | ||
| Q1 25 | $117.0M | $238.3M | ||
| Q4 24 | $110.0M | $208.2M | ||
| Q3 24 | $110.0M | $544.0M | ||
| Q2 24 | $123.0M | $102.0M | ||
| Q1 24 | $122.0M | $4.8M |
营业利润率FNBRPRX
| Q4 25 | 45.1% | 62.4% | ||
| Q3 25 | 52.9% | 70.1% | ||
| Q2 25 | 47.7% | 36.3% | ||
| Q1 25 | 45.8% | 94.0% | ||
| Q4 24 | 31.7% | 60.9% | ||
| Q3 24 | 43.3% | — | ||
| Q2 24 | 49.7% | 50.2% | ||
| Q1 24 | 48.9% | -13.0% |
净利率FNBRPRX
| Q4 25 | 45.9% | 34.4% | ||
| Q3 25 | 41.8% | 47.3% | ||
| Q2 25 | 37.4% | 5.2% | ||
| Q1 25 | 36.2% | 41.9% | ||
| Q4 24 | 34.2% | 35.1% | ||
| Q3 24 | 34.1% | 96.3% | ||
| Q2 24 | 38.9% | 19.0% | ||
| Q1 24 | 38.2% | 0.8% |
每股收益（稀释后）FNBRPRX
| Q4 25 | $0.47 | $0.49 | ||
| Q3 25 | $0.41 | $0.67 | ||
| Q2 25 | $0.36 | $0.07 | ||
| Q1 25 | $0.32 | $0.55 | ||
| Q4 24 | $0.31 | $0.46 | ||
| Q3 24 | $0.30 | $1.21 | ||
| Q2 24 | $0.34 | $0.23 | ||
| Q1 24 | $0.32 | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $2.5B | $618.7M |
| 总债务越低越好 | $1.9B | $9.0B |
| 股东权益账面价值 | $6.8B | $9.7B |
| 总资产 | $50.2B | $19.6B |
| 负债/权益比越低杠杆越低 | 0.28× | 0.92× |
8季度趋势，按日历期对齐
现金及短期投资FNBRPRX
| Q4 25 | $2.5B | $618.7M | ||
| Q3 25 | $2.4B | $938.9M | ||
| Q2 25 | $2.4B | $631.9M | ||
| Q1 25 | $2.4B | $1.1B | ||
| Q4 24 | $2.4B | $929.0M | ||
| Q3 24 | $2.1B | $950.1M | ||
| Q2 24 | $1.9B | $1.8B | ||
| Q1 24 | $1.5B | $843.0M |
总债务FNBRPRX
| Q4 25 | $1.9B | $9.0B | ||
| Q3 25 | $2.1B | $8.9B | ||
| Q2 25 | $2.7B | $8.0B | ||
| Q1 25 | $2.5B | $7.6B | ||
| Q4 24 | $3.0B | $7.6B | ||
| Q3 24 | $2.5B | $7.6B | ||
| Q2 24 | $2.0B | $7.6B | ||
| Q1 24 | $2.1B | $6.1B |
股东权益FNBRPRX
| Q4 25 | $6.8B | $9.7B | ||
| Q3 25 | $6.6B | $9.6B | ||
| Q2 25 | $6.5B | $9.5B | ||
| Q1 25 | $6.4B | $9.8B | ||
| Q4 24 | $6.3B | $10.3B | ||
| Q3 24 | $6.2B | $10.3B | ||
| Q2 24 | $6.1B | $9.8B | ||
| Q1 24 | $6.0B | $9.9B |
总资产FNBRPRX
| Q4 25 | $50.2B | $19.6B | ||
| Q3 25 | $49.9B | $19.3B | ||
| Q2 25 | $49.7B | $18.3B | ||
| Q1 25 | $49.0B | $17.6B | ||
| Q4 24 | $48.6B | $18.2B | ||
| Q3 24 | $48.0B | $18.0B | ||
| Q2 24 | $47.7B | $17.7B | ||
| Q1 24 | $45.9B | $16.1B |
负债/权益比FNBRPRX
| Q4 25 | 0.28× | 0.92× | ||
| Q3 25 | 0.32× | 0.93× | ||
| Q2 25 | 0.41× | 0.84× | ||
| Q1 25 | 0.39× | 0.78× | ||
| Q4 24 | 0.48× | 0.74× | ||
| Q3 24 | 0.40× | 0.74× | ||
| Q2 24 | 0.33× | 0.78× | ||
| Q1 24 | 0.35× | 0.62× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $128.0M | $827.1M |
| 自由现金流经营现金流 - 资本支出 | $99.0M | — |
| 自由现金流率自由现金流/营收 | 27.0% | — |
| 资本支出强度资本支出/营收 | 7.9% | — |
| 现金转化率经营现金流/净利润 | 0.76× | 3.86× |
| 过去12个月自由现金流最近4个季度 | $376.0M | — |
8季度趋势，按日历期对齐
经营现金流FNBRPRX
| Q4 25 | $128.0M | $827.1M | ||
| Q3 25 | $167.0M | $702.6M | ||
| Q2 25 | $123.0M | $364.0M | ||
| Q1 25 | $64.0M | $596.1M | ||
| Q4 24 | $326.0M | $742.5M | ||
| Q3 24 | $-14.0M | $703.6M | ||
| Q2 24 | $85.0M | $658.2M | ||
| Q1 24 | $245.0M | $664.6M |
自由现金流FNBRPRX
| Q4 25 | $99.0M | — | ||
| Q3 25 | $149.0M | — | ||
| Q2 25 | $85.0M | — | ||
| Q1 25 | $43.0M | — | ||
| Q4 24 | $278.0M | — | ||
| Q3 24 | $-46.0M | — | ||
| Q2 24 | $55.0M | — | ||
| Q1 24 | $216.0M | — |
自由现金流率FNBRPRX
| Q4 25 | 27.0% | — | ||
| Q3 25 | 41.5% | — | ||
| Q2 25 | 24.4% | — | ||
| Q1 25 | 13.3% | — | ||
| Q4 24 | 86.3% | — | ||
| Q3 24 | -14.2% | — | ||
| Q2 24 | 17.4% | — | ||
| Q1 24 | 67.7% | — |
资本支出强度FNBRPRX
| Q4 25 | 7.9% | — | ||
| Q3 25 | 5.0% | — | ||
| Q2 25 | 10.9% | — | ||
| Q1 25 | 6.5% | — | ||
| Q4 24 | 14.9% | — | ||
| Q3 24 | 9.9% | — | ||
| Q2 24 | 9.5% | — | ||
| Q1 24 | 9.1% | — |
现金转化率FNBRPRX
| Q4 25 | 0.76× | 3.86× | ||
| Q3 25 | 1.11× | 2.44× | ||
| Q2 25 | 0.95× | 12.06× | ||
| Q1 25 | 0.55× | 2.50× | ||
| Q4 24 | 2.96× | 3.57× | ||
| Q3 24 | -0.13× | 1.29× | ||
| Q2 24 | 0.69× | 6.45× | ||
| Q1 24 | 2.01× | 139.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FNB
暂无分部数据
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
